Bio-Rad iQ-Check Kits Receive AOAC INTERNATIONAL
Approval

Date: 
08/30/2019
iQ-Check-E-coli-O157-H7
The iQ-Check E. coli O157:H7 Real Time PCR Detection Kit is one of the Bio-Rad kits recently granted AOAC INTERNATIONAL approval.

HERCULES, Calif. — August 30, 2019 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced that AOAC INTERNATIONAL has modified its approval for Bio-Rad’s iQ-Check E. coli O157:H7, iQ-Check STEC VirX, and iQ-Check STEC SerO Real-Time PCR Detection Kits to grant their use in detecting foodborne pathogens in a broader range of samples. The iQ-Check Kits are routinely used in food safety programs worldwide and are recognized by international validation organizations.

To obtain approval, a validation study was performed, as part of the AOAC Performance Tested Methods Program, that demonstrated no differences in results between the iQ-Check methods and reference methods.

The iQ-Check E. coli O157:H7 Assay was modified to include 375-gram test portions of raw ground beef (83 percent lean), raw beef trim, and fresh spinach. It was also modified to include 25-gram test portions of raw chicken breast without skin, raw chicken thigh with skin, mechanically separated chicken, and raw ground pork.

The iQ-Check STEC VirX and SerO Assays were modified to include 375-gram test portions of raw ground beef, raw beef trim, and fresh spinach from buffered peptone water.

The AOAC modification included the use of the iQ-Check Free DNA Removal Solution and a single enrichment in buffered peptone water. This method can also allow for the simultaneous enrichment and subsequent detection of Salmonella and pathogenic E. coli from the same sample, providing both time and cost savings when testing large sample sizes.

For more information on Bio-Rad’s iQ-Check Real-Time PCR Test Kits, visit bio-rad.com/iqcheck.

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. IQ-Check is a trademark of Bio-Rad Europe GmbH in certain jurisdictions.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit www.bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Press Contact: 

Bio-Rad Laboratories, Inc.
Wendy Lauer
510-741-5653
wendy_lauer@bio-rad.com

CG Life
Ken Li
312-997-2436
kli@cglife.com